What it's for (Indications)
- Diloxanide + metronidazole is a co-formulated antiparasitic agent indicated for the comprehensive treatment of various forms of amoebiasis caused by *Entamoeba histolytica*.
- This includes acute amoebic dysentery, chronic intestinal amoebiasis, and extra-intestinal amoebiasis such as amoebic liver abscess.
- The combination is particularly valuable as metronidazole effectively targets trophozoites in tissues and systemic sites, while diloxanide furoate eradicates the cysts and trophozoites residing in the intestinal lumen, thereby preventing relapses and reducing the carrier state.
- Furthermore, due to the metronidazole component, this medication is also effective in the treatment of giardiasis caused by *Giardia lamblia* and trichomoniasis caused by *Trichomonas vaginalis*.
- It may also be used in the management of infections caused by susceptible anaerobic bacteria, consistent with metronidazole's established spectrum of activity.
- Comprehensive diagnosis, including stool examination for cysts and trophozoites, is recommended prior to initiation of therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of diloxanide + metronidazole must be determined by a qualified healthcare professional based on the specific infection being treated, the patient's age, weight, and renal/hepatic function. For adults, a common regimen for amoebiasis might involve a combination tablet, for instance, containing Metronidazole 400 mg and Diloxanide Furoate 500 mg, taken orally three times daily for 5 to 10 days. Pediatric dosing is weight-based and requires careful calculation by a physician. It is crucial to complete the full prescribed course of therapy, even if symptoms improve, to ensure complete eradication of the parasite and prevent recurrence or development of resistance. The medication should be taken with food to minimize gastrointestinal upset and enhance tolerability. Patients with significant hepatic impairment may require dosage adjustment due to the metronidazole component, which is extensively metabolized in the liver, to prevent drug accumulation and toxicity. |
Safety & Warnings
Common Side Effects
- Patients receiving diloxanide + metronidazole may experience a range of adverse effects, primarily attributable to the metronidazole component, although diloxanide furoate can contribute to gastrointestinal symptoms.
- Common side effects include nausea, vomiting, abdominal discomfort or cramps, diarrhea, and a characteristic metallic taste in the mouth.
- Other frequently reported adverse reactions encompass headache, dizziness, anorexia, and dark urine (harmless).
- More serious, albeit less common, side effects associated with metronidazole can include neurological disturbances such as peripheral neuropathy (especially with prolonged use or high doses), seizures, aseptic meningitis, and encephalopathy.
- Hypersensitivity reactions, including rash, urticaria, pruritus, and angioedema, may also occur.
- Hematologic effects like reversible neutropenia and thrombocytopenia have been reported.
- Superinfection, particularly candidiasis (oral or vaginal), can develop due to alterations in normal microbial flora.
- Any severe, persistent, or unusual adverse effects should prompt immediate medical evaluation.
Serious Warnings
- Black Box Warning: Metronidazole, a component of this combination therapy, has been shown to be carcinogenic in mice and rats. This was observed in several long-term studies, with dose-dependent increases in the incidence of certain tumors, including pulmonary and hepatic tumors, and lymphomas. While the clinical significance of these findings in humans has not been definitively established, and epidemiological studies in humans have not consistently demonstrated an increased risk of cancer, prudence dictates that diloxanide + metronidazole should be used with caution and reserved for approved indications only. Unnecessary use of this medication should be avoided. The decision to prescribe this medication should carefully weigh the potential benefits against the potential risks, particularly in patients requiring prolonged or repeated courses of therapy. Patients should be thoroughly informed about this potential risk, and the healthcare provider should discuss alternatives or the necessity of treatment if prolonged use is contemplated.
- Patients should be explicitly warned against consuming alcohol or alcohol-containing products during therapy with diloxanide + metronidazole and for at least 72 hours after the last dose, due to the risk of a severe disulfiram-like reaction (e.
- g.
- , flushing, tachycardia, nausea, vomiting, severe headache, hypotension, syncope) caused by metronidazole.
- Caution is advised in patients with pre-existing neurological disorders, as metronidazole can exacerbate or induce neurological adverse effects, including seizures, peripheral neuropathy, and encephalopathy; discontinue treatment immediately if severe neurological symptoms develop.
- The drug should be used with extreme caution in patients with severe hepatic impairment, as metronidazole metabolism is reduced, potentially leading to increased systemic exposure and toxicity; dosage adjustments may be necessary, and liver function should be closely monitored.
- Cases of severe hepatotoxicity, including fatal acute liver failure, have been reported in patients with Crone's syndrome taking metronidazole.
- Blood dyscrasias, including reversible neutropenia and thrombocytopenia, have been reported, necessitating periodic complete blood count monitoring in patients on prolonged therapy.
- Rare but serious dermatological reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been associated with metronidazole.
- Additionally, the possibility of candidiasis superinfection should be considered.
How it Works (Mechanism of Action)
The therapeutic efficacy of diloxanide + metronidazole arises from the complementary mechanisms of action of its two active components. Metronidazole, a nitroimidazole derivative, functions as a prodrug. It enters anaerobic protozoa and bacteria, where its nitro group is reduced by intracellular electron transport proteins. This reduction forms highly reactive free radicals and short-lived cytotoxic intermediates that damage parasitic and bacterial DNA, inhibit nucleic acid synthesis, and disrupt other vital cellular processes, ultimately leading to cell death. This action is specific to anaerobic environments, allowing it to target *Entamoeba histolytica* trophozoites in tissues and systemic circulation, as well as susceptible anaerobic bacteria and *Giardia lamblia*. Diloxanide furoate, conversely, is an amoebicidal agent acting primarily within the intestinal lumen. It is a prodrug that undergoes hydrolysis in the gut to release its active metabolite, diloxanide. While its precise mechanism is not fully elucidated, it is believed to inhibit protein synthesis in *Entamoeba histolytica* trophozoites and exert direct cytotoxic effects on the parasite within the gastrointestinal tract, preventing cyst formation and eliminating luminal parasites, thus reducing the risk of relapse and transmission and minimizing the carrier state.